Cervical Carcinogenesis and Immune Response Gene Polymorphisms: A Review

Table 4

Overview of polymorphism in FAS and FASL genes encoding receptors and association with cervical neoplasia risk.

Gene		Cohort	Cases	Population	Distribution	Risk (OR, 95% CI);	Reference
FAS	c.-670G>A; (rs1800682)	CIN; Cervical cancer	143; 175	Han Chinese	Alleles	A: 1.26 (1.01–1.57); 12.4%	[31]
					Genotypes	GA: 1.11 (0.60–2.02); AA: 1.83 (0.97–3.44)
					Haplotypes; (FAS c.-670/ c.-1377A>G)	G/G: 1.38 (0.80–2.37); A/A: 3.05 (1.28–7.30); 11.3%; A/G: 1.27 (1.00–1.60)
		CIN I; CIN II/III; Cervical cancer	104; 131; 176	Taiwanese	Alleles	CIN I; A: 1.1 (0.8–1.6); CIN II/III; A: 1.1 (0.8–1.6); Cervical cancer; A: 1.5 (1.1–2.0); 20.5%	[32]
		Cervical cancer	2317	Varied	Alleles	A: 0.97 (0.84–1.11)	[33]
FASL	c.-844T>C; (rs736110)	Cervical cancer	314	Chinese	Genotypes	TC: 1.68 (0.78–3.66); CC: 3.05 (1.43–6.52); 41.3%	[34]
			2485	Varied	Alleles	C: 1.12 (0.91–1.36)	[35]

n: number of cases; OR: odds ratio; 95% CI: 95% confidence interval; CIN: cervical intraepithelial neoplasia; PAF: population attributable fraction.
variation and dbSNP reference number.
relative to major allele or major allele homozygotes.
listed if OR > 1.00.
associations listed in bold.